Grants and Contributions:
Title:
COVID-19 Response (VI): Oral DNA Vaccine Development
Agreement Number:
956763
Agreement Value:
$2,821,081.00
Agreement Date:
Sep 4, 2020 - May 31, 2021
Description:
The goal of this project is to develop and clinically evaluate an oral, room temperature stable DNA vaccine candidate for SARS-CoV2. The project will involve the advancement of the bacTRL-Spike COVID-19 vaccine candidate through preclinical development, process development manufacturing scale-up, and first-in-human clinical testing.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Burnaby, British Columbia, CA V5J 5J8
Reference Number:
172-2020-2021-Q2-956763
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
818996241
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 2 time(s). The end date of this agreements has been modified by 61 days.
Amendment Date
Feb 17, 2021
Recipient's Operating Name:
Alexander Graves
Recipient's Legal Name:
Symvivo Corporation
Federal Riding Name:
Burnaby South
Federal Riding Number:
59003
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710
Amendments: